Abatacept in Combination with Methotrexate in Japanese Biologic-naive Patients with Active Rheumatoid Arthritis: a Randomised Placebo-controlled Phase IV Study

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2019 Jan 10

PMID 30622737

Citations 6

Authors

Tsukasa Matsubara

Hiroshi Inoue

Toshihiro Nakajima

Kazuhide Tanimura

Akira Sagawa

Yukio Sato

Kei Osano

Shuji Nagano

Yukitaka Ueki

Tadamasa Hanyu

Koichi Hashizume

Norihito Amano

Yoshiya Tanaka

Tsutomu Takeuchi

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate efficacy and safety of abatacept+methotrexate (MTX) in biologic-naive, anticitrullinated protein antibody (ACPA)-positive Japanese patients with active rheumatoid arthritis (RA) and early erosion versus placebo+MTX.

Methods: In this phase IV, multicentre, double-blind study (NCT01758198), patients were randomised (1:1) to receive intravenous abatacept (~10 mg/kg) or placebo, plus MTX (≥6 mg/week). Primary efficacy objectives were to compare American College of Rheumatology 20 (ACR20) response rates at week 16 and mean change from baseline in van der Heijde-modified total Sharp score (vdH-mTSS) at week 24 between abatacept+MTX and placebo+MTX groups.

Results: Overall, 203 and 202 patients received abatacept+MTX and placebo+MTX, respectively. At week 16, ACR20 response rates were higher in the abatacept (75.4%) versus placebo group (27.7%; p<0.001). Mean change from baseline in vdH-mTSS at week 24 was 0.84 in the abatacept and 1.26 in the placebo group (p=0.017). Radiographic non-progression rates (change in vdH-mTSS≤smallest detectable change (2.4)) were 88.1% and 75.4% in abatacept and placebo groups, respectively. Adjusted mean change from baseline in Disease Activity Score 28 (C-reactive protein) (DAS28 (CRP)) at week 16 demonstrated a numerically greater reduction in the abatacept versus placebo group. Proportions of patients with DAS28 (CRP), Simplified Disease Activity Index and Clinical Disease Activity Index remission up to week 52 were higher in the abatacept versus placebo group. The abatacept safety profile was consistent with previous observations.

Conclusions: Compared with MTX alone, abatacept+MTX improved clinical symptoms and inhibited structural damage progression in ACPA-positive, Japanese patients with RA, early erosion and inadequate response to MTX.

Citing Articles

Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.

Takeuchi T, Kawanishi M, Nakanishi M, Yamasaki H, Tanaka Y Arthritis Rheumatol. 2022; 74(11):1776-1785.

PMID: 35729713 PMC: 9828347. DOI: 10.1002/art.42273.

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study.

Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad H BMC Rheumatol. 2022; 6(1):24.

PMID: 35418172 PMC: 9009012. DOI: 10.1186/s41927-022-00252-4.

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis.

Sato S, Matsumoto H, Temmoku J, Fujita Y, Matsuoka N, Yashiro-Furuya M Medicina (Kaunas). 2021; 57(9).

PMID: 34577837 PMC: 8469009. DOI: 10.3390/medicina57090914.

Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan.

Kawashiri S, Endo Y, Nishino A, Okamoto M, Tsuji S, Takatani A BMC Musculoskelet Disord. 2021; 22(1):506.

PMID: 34074293 PMC: 8171043. DOI: 10.1186/s12891-021-04392-5.

Targeting co-stimulatory molecules in autoimmune disease.

Edner N, Carlesso G, Rush J, Walker L Nat Rev Drug Discov. 2020; 19(12):860-883.

PMID: 32939077 DOI: 10.1038/s41573-020-0081-9.

References

van der Heijde D . How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000; 27(1):261-3. View

. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2002; 47(3):199-203. View

Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A . Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003; 49(6):784-8. DOI: 10.1002/art.11465. View

Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D . Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis. 2004; 64(2):179-82. PMC: 1755378. DOI: 10.1136/ard.2003.018457. View

Kremer J, Dougados M, Emery P, Durez P, Sibilia J, Shergy W . Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(8):2263-71. DOI: 10.1002/art.21201. View

Kremer J, Genant H, Moreland L, Russell A, Emery P, Abud-Mendoza C . Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006; 144(12):865-76. DOI: 10.7326/0003-4819-144-12-200606200-00003. View

Aletaha D, Smolen J . The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007; 21(4):663-75. DOI: 10.1016/j.berh.2007.02.004. View

Nakamura Y . The BioBank Japan Project. Clin Adv Hematol Oncol. 2007; 5(9):696-7. View

Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S . Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2007; 67(8):1096-103. PMC: 2564802. DOI: 10.1136/ard.2007.080002. View

10.

Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A . A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet. 2010; 42(6):515-9. DOI: 10.1038/ng.583. View

11.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

12.

Terao C, Yamada R, Ohmura K, Takahashi M, Kawaguchi T, Kochi Y . The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet. 2011; 20(13):2680-5. DOI: 10.1093/hmg/ddr161. View

13.

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K . Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2011; 71(6):817-24. PMC: 3372319. DOI: 10.1136/ard.2011.200317. View

14.

Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A . Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet. 2012; 44(5):511-6. DOI: 10.1038/ng.2231. View

15.

van der Heijde D, van t Hof M, van Riel P, Theunisse L, Lubberts E, van Leeuwen M . Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990; 49(11):916-20. PMC: 1004262. DOI: 10.1136/ard.49.11.916. View

16.

Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S . Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2012; 23(2):226-35. DOI: 10.1007/s10165-012-0668-z. View

17.

Matsubara T, Yamana S, Tohma S, Takeuchi T, Kondo H, Kohsaka H . Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Mod Rheumatol. 2012; 23(4):634-45. DOI: 10.1007/s10165-012-0722-x. View

18.

Cutolo M, Nadler S . Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 2013; 12(7):758-67. DOI: 10.1016/j.autrev.2013.01.001. View

19.

Smolen J, Landewe R, Breedveld F, Buch M, Burmester G, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013; 73(3):492-509. PMC: 3933074. DOI: 10.1136/annrheumdis-2013-204573. View

20.

Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K . Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2013; 24(5):715-24. DOI: 10.3109/14397595.2013.864224. View